Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ISRCTN97585476) titled 'Evaluation of novel thrombolytic TGD001 in patients with acute ischemic stroke' on Sept. 28.
Study Type: Interventional
Study Design:
Allocation: Randomized controlled trial
Masking: Blinded (masking used)
Control: Placebo
Assignment: Parallel
Purpose: Treatment, Safety
Primary Sponsor: TargED Biopharmaceuticals B.V.
Condition:
Acute ischemic stroke
Circulatory System
Intervention:
The trial consists of two parts and includes prespecified groups of participants with acute ischemic stroke.
Phase 1b is an open-label, single-dose escalation and expansion phase. Participants receive one intravenous administrati...